降脂药物和肺血管疾病:孟德尔的随机化研究
Xingya Yuan1, Peiwei Hong2, JinQiu Zhou3
1Department of Pneumoconiosis/Pulmonary and Critical Care Medicine West China School of Public Health and West China Fourth Hospital, Sichuan University Chengdu China.
Pulmonary circulation
|January 24, 2025
概括
这项研究使用了门德尔的随机化来探索降脂药物如何影响肺血管疾病. NPC1L1和PCSK9抑制剂可能会增加肺动脉高血压风险,而APOB抑制剂可能会降低肺栓塞和心脏病风险.
科学领域:
- 心血管遗传学 心血管遗传学
- 肺部医学 肺部医学
- 药物基因组学 药物基因组学
背景情况:
- 降脂药在治疗肺血管疾病中的作用尚未得到充分证实.
- 现有证据有限,需要进一步调查因果关系.
研究的目的:
- 研究特定的降脂药物标 (APOB,CETP,HMGCR,NPC1L1,PCSK9) 对肺动脉高血压 (PAH),肺栓塞 (PE) 和肺心脏病 (PHD) 的因果关系.
- 利用孟德尔的随机化 (MR) 方法,使用遗传数据推断这些因果关系.
主要方法:
- 利用了全基因组关联研究 (GWAS) 对低密度脂蛋白胆固醇 (LDL-C) 和肺血管疾病结局的总结统计数据.
- 在药物位附近选择的单核酸多态 (SNPs) 作为降脂药物效应的遗传代理.
- 采用逆方差加权 (IVW) 和MR-Egger方法来估计因果关系,使用来自FinnGen和UK Biobank的数据.
主要成果:
- 由NPC1L1和PCSK9介导的LDL-C与增高的PAH风险显著相关.
- 通过APOB调节的LDL-C在FinnGen和英国生物银行队列中显示出与降低PE和PHD风险的显著关联.
- 通过CETP或HMGCR调解的LDL-C与PAH,PE或PHD风险没有发现显著的关联.
结论:
- 这项MR研究提供了NPC1L1和PCSK9抑制的因果作用的证据,表明PAH风险的潜在增加.
- 抑制APOB似乎具有保护作用,可能降低PE和PHD的风险.
- 这些发现有助于理解脂质代谢和肺血管疾病之间的复杂相互作用,为潜在的治疗策略提供信息.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
526
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
526
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
01:23Antihypertensive Drugs: Vasodilators
470
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
470
01:30Pulmonary Hypertension: Classification and Pathogenesis
148
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
148
01:19Antiasthma Drugs: Leukotriene Modifiers
240
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
240
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
133
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
133